Thelansis

  Autoimmune uveitis (AU) is a specific organ pathology characterized by irreversible ocular lesions. It typically afflicts individuals during their peak years of productivity and is a prominent contributor to visual impairment and blindness. The etiology of this disorder often implicates immune reactions directed against retinal proteins. Despite advancements, the precise cellular dynamics and pathogenic pathways responsible for retinal damage in uveitis remain elusive. Navigating the management of AU poses a significant clinical challenge, compounded by the need for more randomized clinical trials systematically assessing the efficacy of various therapeutic modalities. Apart from topical interventions, a range of therapeutic avenues exists, although the absence of a standardized treatment protocol complicates clinical decision-making. Current clinical guidelines advocate corticosteroids as the primary pharmacological intervention for individuals presenting with active...